- Home
- ACXP vs RDI Comparison
ACXP vs RDI Comparison
Compare ACXP & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACXP | RDI |
|---|---|---|
| Founded | 2017 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 25.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACXP | RDI |
|---|---|---|
| Price | $3.19 | $1.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $143.67 | N/A |
| AVG Volume (30 Days) | 77.3K | ★ 473.5K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $211,292,000.00 |
| Revenue This Year | N/A | $1.06 |
| Revenue Next Year | N/A | $10.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $3.17 | $1.02 |
| 52 Week High | $25.00 | $1.87 |
Technical Indicators
Market Signals| Indicator | ACXP | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 27.74 |
| Support Level | $3.98 | $1.02 |
| Resistance Level | $3.63 | $1.10 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 2.11 | 4.00 |
Price Performance
Historical ComparisonAbout ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.